# **Data Changes for the CCDD MAY Release Candidate 2023**

## **Based on the QA Release Generation** 20230501

|  |  |
| --- | --- |
| Data entered by | A.Raghuveer |
| Data checked by | J.Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8001230 | saquinavir |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9014634 | budesonide 182 mcg per actuation and formoterol fumarate 5.8 mcg per actuation and glycopyrronium (glycopyrronium bromide) 8.2 mcg per actuation pressurized inhalation | budésonide 182 mcg par actionnement et fumarate de formotérol 5,8 mcg par actionnement et glycopyrronium (bromure de glycopyrronium) 8,2 mcg par actionnement inhalation en flacon pressurisé | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9000001 | meperidine hydrochloride 50 mg oral tablet |
| 9004151 | saquinavir (saquinavir mesylate) 500 mg oral tablet |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For all DINs, they have had additional UoP added. All products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 89353 | 2408775 | APO-QUINAPRIL/HCTZ (hydrochlorothiazide 12.5 mg and quinapril (quinapril hydrochloride) 20 mg oral tablet) APOTEX INC | Dormant 2023.03.17 |
| 44058 | 2155966 | CIPRO (ciprofloxacin (ciprofloxacin hydrochloride) 500 mg oral tablet) BAYER INC | Canceled post-market Expiry 2023.04.30 |
| 18316 | 2138018 | DEMEROL (meperidine hydrochloride 50 mg oral tablet) SANOFI-AVENTIS CANADA INC | Canceled post-market Expiry 2023.04.18 |
| 10918 | 765996 | DIAMICRON (gliclazide 80 mg oral tablet) SERVIER CANADA INC | Canceled post-market Expiry 2023.04.30 |
| 76489 | 2279320 | INVIRASE (saquinavir (saquinavir mesylate) 500 mg oral tablet) HOFFMANN-LA ROCHE LIMITED | Canceled post-market Expiry 2023.04.30 |
| 92673 | 2442361 | JAMP-MONTELUKAST (montelukast (montelukast sodium) 5 mg chewable tablet) JAMP PHARMA CORPORATION | Canceled post-market 2023.04.20 |
| 95758 | 2468921 | MELPHALAN FOR INJECTION (melphalan (melphalan hydrochloride) 50 mg per vial powder for solution for injection with diluent solution) APOTEX INC | Dormant 2023.04.13 |
| 90597 | 2421348 | MINT-RAMIPRIL (ramipril 15 mg oral capsule) MINT PHARMACEUTICALS INC | Dormant 2023.04.05 |
| 93058 | 2445352 | PRIVA-SERTRALINE (sertraline (sertraline hydrochloride) 25 mg oral capsule) NORA PHARMA INC | Canceled post-market Expiry 2023.04.30 |
| 43137 | 77700526 | ZOFRAN (ondansetron (ondansetron hydrochloride dihydrate) 2 mg per mL solution for injection 20 mL vial) NOVARTIS PHARMACEUTICALS CANADA INC | Canceled post-market Expiry 2023.02.28 |
| 43137 | 77700527 | ZOFRAN (ondansetron (ondansetron hydrochloride dihydrate) 4 mg per 2 mL solution for injection ampoule) NOVARTIS PHARMACEUTICALS CANADA INC | Canceled post-market Expiry 2023.02.28 |
| 47565 | 2229639 | ZOFRAN (ondansetron (ondansetron hydrochloride dihydrate) 4 mg per 5 mL oral solution) NOVARTIS PHARMACEUTICALS CANADA INC | Canceled post-market Expiry 2022.12.31 |
| 43137 | 77700528 | ZOFRAN (ondansetron (ondansetron hydrochloride dihydrate) 8 mg per 4 mL solution for injection ampoule) NOVARTIS PHARMACEUTICALS CANADA INC | Canceled post-market Expiry 2023.02.28 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the DECEMBER 2022 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
|  | lidocaine 0.8 % cutaneous gel | 98886 | 02499118 | AFTER SUN GEL (lidocaine 0.8 % cutaneous gel) FRUIT OF THE EARTH, INC | STAY |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 3dce03aee39c1bd6128494c330b8624e | budesonide 2.3 mg tablet for rectal solution with diluent solution | 16264 | 02052431 | ENTOCORT ENEMA (budesonide 2.3 mg tablet for rectal solution with diluent solution) TILLOTTS PHARMA GMBH | ADD |
| aafef467b6840d53ca7bdbbacafb5e83 | ravulizumab 1100 mg per 11 mL solution for injection | 102244 | 02533456 | ULTOMIRIS (ravulizumab 1100 mg per 11 mL solution for injection) ALEXION PHARMA GMBH | ADD |
| 3dc432f22c81daba877f1139e07ee74a | ravulizumab 300 mg per 3 mL solution for injection | 102243 | 02533448 | ULTOMIRIS (ravulizumab 300 mg per 3 mL solution for injection) ALEXION PHARMA GMBH | ADD |